Fig. 1From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysisRecurrence-free (left, log-rank p = 0.98) and overall survival (right, log-rank p = 0.37) of all adjuvant stage III NY-ESO-1 vaccine clinical trial patients stratified by each of the three individual trialsBack to article page